475 related articles for article (PubMed ID: 19838783)
1. The biological properties of E6 and E7 oncoproteins from human papillomaviruses.
Ghittoni R; Accardi R; Hasan U; Gheit T; Sylla B; Tommasino M
Virus Genes; 2010 Feb; 40(1):1-13. PubMed ID: 19838783
[TBL] [Abstract][Full Text] [Related]
2. Protein intrinsic disorder and human papillomaviruses: increased amount of disorder in E6 and E7 oncoproteins from high risk HPVs.
Uversky VN; Roman A; Oldfield CJ; Dunker AK
J Proteome Res; 2006 Aug; 5(8):1829-42. PubMed ID: 16889404
[TBL] [Abstract][Full Text] [Related]
3. Roles of E6 and E7 Human Papillomavirus Proteins in Molecular Pathogenesis of Cervical Cancer.
Taghizadeh E; Jahangiri S; Rostami D; Taheri F; Renani PG; Taghizadeh H; Gheibi Hayat SM
Curr Protein Pept Sci; 2019; 20(9):926-934. PubMed ID: 31244421
[TBL] [Abstract][Full Text] [Related]
4. Molecular Mechanisms of MmuPV1 E6 and E7 and Implications for Human Disease.
Romero-Masters JC; Lambert PF; Munger K
Viruses; 2022 Sep; 14(10):. PubMed ID: 36298698
[TBL] [Abstract][Full Text] [Related]
5. Transforming Properties of Beta-3 Human Papillomavirus E6 and E7 Proteins.
Minoni L; Romero-Medina MC; Venuti A; Sirand C; Robitaille A; Altamura G; Le Calvez-Kelm F; Viarisio D; Zanier K; Müller M; Accardi R; Tommasino M
mSphere; 2020 Jul; 5(4):. PubMed ID: 32669468
[TBL] [Abstract][Full Text] [Related]
6. Evidence for direct interaction between the oncogenic proteins E6 and E7 of high-risk human papillomavirus (HPV).
Lim J; Lilie H; Kalbacher H; Roos N; Frecot DI; Feige M; Conrady M; Votteler T; Cousido-Siah A; Corradini Bartoli G; Iftner T; Trave G; Simon C
J Biol Chem; 2023 Aug; 299(8):104954. PubMed ID: 37354975
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms underlying human papillomavirus E6 and E7 oncoprotein-induced cell transformation.
Mittal S; Banks L
Mutat Res Rev Mutat Res; 2017; 772():23-35. PubMed ID: 28528687
[TBL] [Abstract][Full Text] [Related]
8. The Mus musculus Papillomavirus Type 1 E7 Protein Binds to the Retinoblastoma Tumor Suppressor: Implications for Viral Pathogenesis.
Wei T; Grace M; Uberoi A; Romero-Masters JC; Lee D; Lambert PF; Munger K
mBio; 2021 Aug; 12(4):e0227721. PubMed ID: 34465025
[TBL] [Abstract][Full Text] [Related]
9. The biology of beta human papillomaviruses.
Tommasino M
Virus Res; 2017 Mar; 231():128-138. PubMed ID: 27856220
[TBL] [Abstract][Full Text] [Related]
10. Systematic Analysis of IL-1 Cytokine Signaling Suppression by HPV16 Oncoproteins.
Castagnino P; Kim HW; Lam LKM; Basu D; White EA
J Virol; 2022 Nov; 96(22):e0132622. PubMed ID: 36342298
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of Toll-Like Receptor 9 Expression by Beta Human Papillomavirus 38 and Implications for Cell Cycle Control.
Pacini L; Savini C; Ghittoni R; Saidj D; Lamartine J; Hasan UA; Accardi R; Tommasino M
J Virol; 2015 Nov; 89(22):11396-405. PubMed ID: 26339055
[TBL] [Abstract][Full Text] [Related]
12. Control of interferon signaling in human papillomavirus infection.
Koromilas AE; Li S; Matlashewski G
Cytokine Growth Factor Rev; 2001; 12(2-3):157-70. PubMed ID: 11325599
[TBL] [Abstract][Full Text] [Related]
13. The human papillomavirus family and its role in carcinogenesis.
Tommasino M
Semin Cancer Biol; 2014 Jun; 26():13-21. PubMed ID: 24316445
[TBL] [Abstract][Full Text] [Related]
14. Bioinformatics analysis of HPV-68 E6 and E7 oncoproteins for designing a therapeutic epitope vaccine against HPV infection.
Dong D; Zhu Y; Aili Z; Chen Z; Ding J
Infect Genet Evol; 2020 Jul; 81():104266. PubMed ID: 32114254
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of transforming properties of E6 and E7 from different beta human papillomavirus types.
Cornet I; Bouvard V; Campo MS; Thomas M; Banks L; Gissmann L; Lamartine J; Sylla BS; Accardi R; Tommasino M
J Virol; 2012 Feb; 86(4):2366-70. PubMed ID: 22171257
[TBL] [Abstract][Full Text] [Related]
16. Modulation of microRNA-mRNA Target Pairs by Human Papillomavirus 16 Oncoproteins.
Harden ME; Prasad N; Griffiths A; Munger K
mBio; 2017 Jan; 8(1):. PubMed ID: 28049151
[TBL] [Abstract][Full Text] [Related]
17. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia.
Zumbach K; Kisseljov F; Sacharova O; Shaichaev G; Semjonova L; Pavlova L; Pawlita M
Int J Cancer; 2000 Feb; 85(3):313-8. PubMed ID: 10652419
[TBL] [Abstract][Full Text] [Related]
18. E6^E7, a novel splice isoform protein of human papillomavirus 16, stabilizes viral E6 and E7 oncoproteins via HSP90 and GRP78.
Ajiro M; Zheng ZM
mBio; 2015 Feb; 6(1):e02068-14. PubMed ID: 25691589
[TBL] [Abstract][Full Text] [Related]
19. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16.
Hasan UA; Bates E; Takeshita F; Biliato A; Accardi R; Bouvard V; Mansour M; Vincent I; Gissmann L; Iftner T; Sideri M; Stubenrauch F; Tommasino M
J Immunol; 2007 Mar; 178(5):3186-97. PubMed ID: 17312167
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus E6/E7 oncoproteins promote radiotherapy-mediated tumor suppression by globally hijacking host DNA damage repair.
Bruyere D; Roncarati P; Lebeau A; Lerho T; Poulain F; Hendrick E; Pilard C; Reynders C; Ancion M; Luyckx M; Renard M; Jacob Y; Twizere JC; Peiffer R; Peulen O; Delvenne P; Hubert P; McBride A; Gillet N; Masson M; Herfs M
Theranostics; 2023; 13(3):1130-1149. PubMed ID: 36793865
[No Abstract] [Full Text] [Related]
[Next] [New Search]
